Contraceptives market seen topping $43 billion by 2030

The Business Research Company says the global contraceptives market is on track to exceed $43 billion by 2030, powered by family planning awareness, long-acting methods and digital health tools. North America is expected to remain the largest regional market, while intrauterine devices are forecast to be the top product category.

Why it matters: - The contraceptives market is expanding as demand rises for family planning, reproductive health access and longer-acting methods. - The segment is expected to top $43 billion by 2030, making it a meaningful slice of the broader pharmaceuticals industry. - Growth in digital health, telehealth and online access is reshaping how consumers find and manage contraception.

What happened: - The Business Research Company published its Contraceptives Global Market Report 2026 with forecasts through 2035. - The report says the contraceptives market will surpass $43 billion by 2030. - The market is forecast to grow at an 8% compound annual rate through 2030. - The report places contraceptives at about 81% of the Genito-Urinary Drugs segment by 2030. - The report says the category will represent nearly 2% of the broader pharmaceuticals market in 2030.

The details: - North America is projected to be the largest regional market in 2030 at $15 billion, up from $11 billion in 2025. - The U.S. is forecast to reach $13 billion by 2030, up from $10 billion in 2025. - The report links North American growth to reproductive health awareness, sexual health education, government support and wider insurance coverage for modern methods. - Intra-uterine devices are forecast to be the largest product segment in 2030, with 27% of the market, or about $12 billion. - The product mix also includes oral contraceptive pills, topical contraceptives, injectables, diaphragms, vaginal rings, condoms, contraceptive sponges and subdermal implants. - The market is also segmented by age groups 15–24, 25–34, 35–44 and over 44, plus distribution through hospital pharmacies, independent pharmacies, online pharmacies, clinics and other outlets. - The report says rising family planning awareness is adding about 2.4% annual growth. - It says efforts to reduce unintended pregnancies and sexually transmitted diseases are adding about 2.2% annual growth. - It says contraceptive technology advances are adding about 2.1% annual growth.

Between the lines: - The market remains fragmented, with the top 10 players accounting for just 7% of revenue in 2025. - Bayer AG led global contraceptive sales in 2025 with a 2% share. - Other top players in 2025 included Organon & Co., Reckitt Benckiser Group plc and CooperSurgical at 1% each, followed by Pfizer Inc. and Teva Pharmaceutical Industries Ltd. at 0.4% each. - The report points to barriers tied to regulation, clinical safety standards and high R&D spending. - Digital tracking is becoming a bigger part of the category as users look for personalized cycle insights and reproductive health monitoring. - In May 2026, Oura added a hormonal birth control feature to its Cycle Insights platform. - The feature tracks hormonal contraceptive combinations and analyzes biometric data to help users understand hormonal changes and manage cycles. - The report says companies are also using artificial intelligence for personalized health insights and tracking.

What’s next: - The report says several categories will add more than $13 billion in combined value between 2025 and 2030. - Condoms are forecast to add $4 billion. - Oral contraceptives and intra-uterine devices are each forecast to add $3 billion. - Injectables and subdermal implants are each forecast to add $1 billion. - Future competition is likely to center on safer formulations, easier delivery methods, broader family planning programs and more digital health integration.

The bottom line: - Contraceptives remain a steady-growth healthcare market, but the biggest upside is shifting toward long-acting methods, digital tools and wider access across pharmacy and online channels.